Drug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination used

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloUniversidad Nacional de La Plataes
cic.versioninfo:eu-repo/semantics/publishedVersiones
dc.date.accessioned2021-04-08T14:39:47Z
dc.date.available2021-04-08T14:39:47Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/10875
dc.titleDrug Utilization Study on Oral Contraceptives provided from Social Security, Buenos Aires-Argentina: Risk and cost analysis according to the type of combination useden
dc.typeArtículoes
dcterms.abstractOral contraceptive pill is the most prescribed option to avoid birth-rate around the world. It is a combination of estrogens/progestin. Unfortunately, new combinations raise the risk of thrombosis. To determine the prescription profile and the incidence of thrombotic events associated to oral contraceptive use, we developed the present study. Method: It is a drug utilization study among beneficiaries of Buenos Aires Social Security Organization. Variables studied were age, sex, combination consumed, doses, co-morbidities, thrombotic events. Results: 69,653 women were enrolled in the study. 66,043 of them (94.84%) used new progestogen generation combination (desogestrel, gestodene, drospirenone,) while 3610 (5.18%) used either levonorgestrel or norgestrel as progestin. The number of thrombotic events (either depth vein thrombosis of lower limbs, thromboembolism or arterial thrombosis) was 77 (75 with new progestin and 2 using 1st/2nd generation options). Adjusting these values to 100,000 users; the occurrence of thrombotic events were doubled with new generation progestins when compared to older options. The price of the new generation combinations were 10.2 times more expensive that the safer ones. Conclusion: Among the beneficiaries of Buenos Aires State Social Security, the users of oral contraceptives with new generation progestin denote a greater risk of thrombotic events when compared with users of levonorgestrel or norgestrel. Public reproductive health policies that provide contraceptives to the population are crucial in guaranteeing rights such as avoiding unwanted pregnancies and reproductive planning. However, the combinations provided should not expose population to additional and unnecessary risks.en
dcterms.creator.authorMarín, Lupees
dcterms.creator.authorBlanco, Luises
dcterms.creator.authorMarín, Ginaes
dcterms.creator.authorAgüero, Sergioes
dcterms.creator.authorPagnotta, Marianaes
dcterms.creator.authorMarín, Gustavo H.es
dcterms.extent198-201es
dcterms.identifier.otherdoi:10.22270/jddt.v10i5.4315es
dcterms.identifier.otherISSN 2250-1177es
dcterms.identifier.urlRecurso completoes
dcterms.isPartOf.issuevol. 10, n. 5es
dcterms.isPartOf.seriesJournal of Drug Delivery and Therapeuticses
dcterms.issued2020-09
dcterms.languageIngléses
dcterms.licenseAttribution-NonCommercial 4.0 International (BY-NC 4.0)es
dcterms.subjectOral contraceptivesen
dcterms.subjectThrombosisen
dcterms.subjectProgestinen
dcterms.subjectRisken
dcterms.subjectPublic healthen
dcterms.subject.materiaCiencias Médicas y de la Saludes

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Drug Utilization Study on Oral Contraceptives.pdf-PDFA.pdf
Tamaño:
783.66 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo